Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New stimulant EB-1020 put to the test: will it be abused?

NCT ID NCT02144415

Knowledge-focused Sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc. Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study looked at whether a new drug called EB-1020 has abuse potential in 80 healthy adults who use stimulants recreationally. Participants received single doses of EB-1020, d-amphetamine, or placebo, and rated how much they liked the drug. The goal was to see if EB-1020 produces a 'high' similar to other stimulants.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
EB-1020 immediate-release capsules
What this could lead to
If EB-1020 shows low abuse potential, it may be developed as a safer stimulant alternative for conditions like ADHD.
What could go wrong
This is an early Phase 1 study in healthy volunteers, not patients. The results may not predict real-world abuse or effectiveness.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 1

The first testing in people. Mainly checks safety and dose, usually in a small group.

Participants

80 people

The number who actually took part.

Started

May 2014

Finished

Jul 2014

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 55 years

Sex

Male participants only

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Subjects must be healthy male nondependent recreational drug users 2. Subjects must be 18 to 55 years old, inclusive. 3. Subjects must have greater than or equal to 10 lifetime nontherapeutic experiences with central nervous system (CNS) stimulants (e.g., amphetamines, cocaine, methylphenidate), greater than or equal to 1 nontherapeutic use of prescription stimulants within the 12 months prior to Screening, and greater than or equal to 1 nontherapeutic use of a CNS stimulant within the 12 weeks prior to Screening. Exclusion Criteria: 1. Subjects that are deemed medically unsuitable or unlikely to comply with the study protocol for any reason. 2. Subjects who do not pass Qualification Phase criteria to be eligible for the Treatment Phase.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Drug users are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

attention deficit hyperactivity disorder, inattentive type Drug Misuse

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Drug users Healthy volunteers

Contacts and locations

Locations

  • Vince and Associates Clinical Research, Inc.

    Overland Park, Kansas, 66212, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.